Acadia Pharmaceuticals (ACAD) Long-Term Deferred Tax (2022 - 2026)

Acadia Pharmaceuticals' Long-Term Deferred Tax history runs 4 years deep, the most recent figure standing at $249.6 million for Q1 2026.

• In Q1 2026, Long-Term Deferred Tax changed N/A year-over-year to $249.6 million; the TTM figure through Mar 2026 stood at $249.6 million (changed N/A YoY), while the FY2025 annual figure was $249.9 million, changed N/A from the prior year.
• Long-Term Deferred Tax was $249.6 million for Q1 2026 at Acadia Pharmaceuticals, roughly flat from $249.9 million in the prior quarter.
• In the past five years, Long-Term Deferred Tax ranged from a high of $249.9 million in Q4 2025 to a low of $1.2 million in Q4 2022.
• Historically, Long-Term Deferred Tax has averaged $126.9 million across 4 years, with a median of $128.2 million in 2023.
• Biggest YoY gain for Long-Term Deferred Tax was 466.67% in 2023; the steepest drop was 466.67% in 2023.
• A 4-year view of Long-Term Deferred Tax shows it stood at $1.2 million in 2022, then soared by 466.67% to $6.8 million in 2023, then jumped by 3574.69% to $249.9 million in 2025, then retreated by 0.1% to $249.6 million in 2026.
• The last three Long-Term Deferred Tax figures came in at $249.6 million (Q1 2026), $249.9 million (Q4 2025), and $6.8 million (Q4 2023), per Business Quant data.